Beyond Air reported $1.8 million in revenue for Q2 FY2026 with a net loss of $7.9 million, or $11.00 per share. The company reaffirmed full-year 2026 revenue guidance of $8 million and 2027 guidance of $16-$18 million. Beyond Air secured an up to $30.1 million financing, including $10.2 million in upfront proceeds and warrants tied to FDA approval for its second-generation LungFit PH system. The company regained Nasdaq compliance and entered a national GPO agreement expanding reach by nearly 2,000 hospitals. Additionally, Beyond Air announced a transition of its fiscal year-end from March 31 to December 31 effective December 31, 2026. Beyond Air is a medical device and biopharmaceutical company focused on nitric oxide therapies for respiratory illnesses.

Beyond Air, Inc. received confirmation from Nasdaq that it has regained compliance with the minimum bid price requirement following a 1-for-20 reverse stock split effected on July 13, 2026. The company's common stock closed at or above $1.00 per share for 17 consecutive trading days ending August 4, 2026. Nasdaq imposed a Discretionary Panel Monitor for one year, during which the company cannot submit a new compliance plan if it fails to meet listing requirements again. Beyond Air, Inc. operates in the medical device industry, developing respiratory care solutions.

Beyond Air, Inc. entered into a securities purchase agreement on July 29, 2026, for a private placement expected to yield approximately $10.2 million in gross proceeds at closing. The company issued 167,011 shares of common stock and pre-funded warrants for up to 1,638,835 additional shares, each accompanied by Series A and Series B warrants exercisable at $5.51 per share. Institutional investors paid $5.66 per unit, while directors and executive officers including CEO Robert Goodman and CFO Daniel Moorhead paid $5.76 per unit. Total potential proceeds reach up to $30.1 million if all warrants are exercised for cash. The closing is expected on July 31, 2026, with net proceeds designated for working capital and general corporate purposes. Beyond Air operates in the medical device and biopharmaceutical industry, focusing on nitric oxide therapies for respiratory conditions.

Beyond Air, Inc. approved and filed a 1-for-20 reverse stock split to raise its common stock bid price above $1.00 per share to regain compliance with Nasdaq Listing Rule 5550(a)(2). The split will become effective at 12:01 a.m. ET on July 13, 2026, and the company's common stock will begin trading on a split-adjusted basis on that date. Beyond Air, Inc. operates in the medical technology industry, providing respiratory therapy solutions.

Beyond Air, Inc. announced its financial results for the fiscal quarter and year ended March 31, 2026, and approved a change in its fiscal year-end from March 31 to December 31, effective December 31, 2026. The company will report a nine-month transition period from April 1, 2026, through December 31, 2026. Beyond Air, Inc. operates in the medical technology industry, providing respiratory solutions for patients with lung disease.

Beyond Air, Inc. stockholders approved a reverse stock split with a ratio of 1-for-20, as determined by the Board of Directors. The company intends to implement the following reverse split to raise its common stock bid price above $1.00 per share to maintain Nasdaq compliance. Beyond Air, Inc. is a medical technology company that provides respiratory and respiratory-related products and services.